tradingkey.logo

Evoke Pharma Inc

EVOK

5.220USD

+0.140+2.76%
終値 09/19, 16:00ET15分遅れの株価
7.79M時価総額
損失額直近12ヶ月PER

Evoke Pharma Inc

5.220

+0.140+2.76%
詳細情報 Evoke Pharma Inc 企業名
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of drugs to treat gastrointestinal (GI) disorders and diseases. The Company operates through the development and commercialization of pharmaceutical products. It is developing its product, Gimoti (metoclopramide) nasal spray, the first and only nasally administered product indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. It developed Gimoti, a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti is a novel formulation of metoclopramide offering systemic delivery by nasal spray administration. It has developed the nasal formulation of metoclopramide to provide its targeted patient population with acute or recurrent symptoms of diabetic gastroparesis.
企業情報
企業コードEVOK
会社名Evoke Pharma Inc
上場日Sep 25, 2013
最高経営責任者「CEO」Mr. Matthew J. (Matt) D'Onofrio
従業員数3
証券種類Ordinary Share
決算期末Sep 25
本社所在地420 Stevens Avenue
都市SOLANA BEACH
証券取引所NASDAQ Capital Market Consolidated
United States of America
郵便番号92075
電話番号18583451494
ウェブサイトhttps://evokepharma.com/
企業コードEVOK
上場日Sep 25, 2013
最高経営責任者「CEO」Mr. Matthew J. (Matt) D'Onofrio
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+15.50%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-0.04%
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
133.00
-0.75%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
27.00
-3.57%
Mr. Greg Pyszcymuka
Mr. Greg Pyszcymuka
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Dr. Marilyn R. Carlson, M.D.
Dr. Marilyn R. Carlson, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Benjamin C. (Ben) Smeal
Mr. Benjamin C. (Ben) Smeal
Independent Director
Independent Director
--
--
Mr. Daniel Kontoh-Boateng
Mr. Daniel Kontoh-Boateng
Investor Contact
Investor Contact
--
--
Ms. Vickie W. Reed
Ms. Vickie W. Reed
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Matthew J. (Matt) D'Onofrio
Mr. Matthew J. (Matt) D'Onofrio
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
9.82K
+15.50%
Mr. Cam L. Garner
Mr. Cam L. Garner
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
2.33K
-0.04%
Dr. Malcolm R. Hill, Pharm.D.
Dr. Malcolm R. Hill, Pharm.D.
Independent Director
Independent Director
133.00
-0.75%
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
Independent Director
Independent Director
27.00
-3.57%
Mr. Greg Pyszcymuka
Mr. Greg Pyszcymuka
Independent Director
Independent Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
収益内訳
FY2025Q1
FY2024
FY2024Q1
FY2023
FY2022
FY2021
FY2020
データなし
地域別USD
会社名
収益
比率
United States
3.08M
0.00%
事業別
地域別
データなし
株主
更新時刻: Fri, Aug 29
更新時刻: Fri, Aug 29
株主統計
種類
株主統計
株主統計
比率
Morgan Stanley Smith Barney LLC
10.51%
Nantahala Capital Management, LLC
9.51%
Bleichroeder LP
4.41%
Citadel Advisors LLC
0.80%
D'Onofrio (Matthew J)
0.63%
他の
74.14%
株主統計
株主統計
比率
Morgan Stanley Smith Barney LLC
10.51%
Nantahala Capital Management, LLC
9.51%
Bleichroeder LP
4.41%
Citadel Advisors LLC
0.80%
D'Onofrio (Matthew J)
0.63%
他の
74.14%
種類
株主統計
比率
Investment Advisor
15.05%
Hedge Fund
10.44%
Individual Investor
1.28%
Investment Advisor/Hedge Fund
0.51%
他の
72.72%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
34
272.65K
18.26%
-174.03K
2025Q1
37
273.02K
18.29%
-164.20K
2024Q4
38
286.68K
19.29%
-150.95K
2024Q3
39
276.54K
27.87%
-57.30K
2024Q2
39
330.88K
325.68%
-1.95K
2024Q1
46
331.84K
45.81%
+48.22K
2023Q4
42
12.65K
4.52%
-4.41K
2023Q3
46
12.52K
4.50%
-16.16K
2023Q2
47
11.87K
4.27%
-16.69K
2023Q1
53
12.69K
4.56%
-16.37K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Morgan Stanley Smith Barney LLC
64.00
0%
+33.00
+106.45%
Mar 31, 2025
Nantahala Capital Management, LLC
148.15K
9.92%
--
--
Mar 31, 2025
Bleichroeder LP
68.75K
4.61%
--
--
Mar 31, 2025
Citadel Advisors LLC
24.80K
1.66%
+24.80K
--
Mar 31, 2025
D'Onofrio (Matthew J)
9.82K
0.66%
+1.32K
+15.50%
Mar 24, 2025
Geode Capital Management, L.L.C.
7.93K
0.53%
--
--
May 31, 2025
Kowieski (Mark A.)
4.92K
0.33%
+4.92K
--
Mar 24, 2025
Gonyer (David A)
2.36K
0.16%
-1.00
-0.04%
Mar 24, 2025
Garner (Cam L)
2.33K
0.16%
-1.00
-0.04%
Mar 24, 2025
Tower Research Capital LLC
213.00
0.01%
+213.00
--
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Sep 6
更新時刻: Sat, Sep 6
銘柄名
比率
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
比率0%
配当金
過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
日付
種類
比率
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
Jul 30, 2024
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
May 20, 2022
Merger
12→1
KeyAI